KATHI PRICE: Open Payments
NPI 1477656023 · COEBURN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$830 in 23 payments from 6 companies in 2025. Trend: 2023 $1,021 · 2024 $579 · 2025 $830
Food & beverage: $830
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $232 |
| AstraZeneca Pharmaceuticals LP | 7 | $227 |
| Gilead Sciences, Inc. | 4 | $151 |
| Novo Nordisk Inc | 3 | $148 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| ABBVIE INC. | 2 | $36 |
Products named: CAPLYTA, Ozempic, AIRSUPRA, Epclusa, FARXIGA, XIFAXAN, UBRELVY, VRAYLAR.
Industry payments across VA — which companies pay providers there.
